ReviewVirchows Archiv : an international journal of pathology2026
The evolution of prostate cancer grading: from Gleason score to risk taxonomy and the artificial intelligence revolution.
Review in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histopathological grading remains the cornerstone of risk stratification in prostate cancer, yet conventional Gleason-based assessment is limited by interobserver variability and by the biological heterogeneity concealed within Gleason pattern 4. This review examines the evolution of prostate cancer grading from the original Gleason system to contemporary Grade Groups and to newer morphology-based frameworks that seek to refine prognostic stratification. Particular attention is given to the distinction between patterns 3 and 4, which remains clinically pivotal but diagnostically challenging, especially in the setting of poorly formed glands. By contrast, cribriform architecture has emerged as one of the most reproducible and prognostically adverse components of pattern 4. Intraductal carcinoma of the prostate (IDC-P), which often overlaps morphologically and biologically with cribriform carcinoma, is similarly associated with aggressive disease and is now addressed within a more unified diagnostic and grading framework following the recent joint GUPS/ISUP recommendations. Outcome-based morphometric studies further suggest that a diameter threshold of approximately 0.25 mm can identify large cribriform glands with particularly adverse behavior, although standardization remains incomplete. These observations have contributed to the development of a risk-oriented taxonomy in which adverse architectural features may carry greater prognostic weight than numerical grade alone. Finally, we discuss how digital pathology and artificial intelligence are extending this conceptual shift by improving diagnostic reproducibility, enabling quantitative detection of cribriform morphology and supporting outcome-oriented histology-based risk prediction. Together, these developments suggest that prostate cancer grading is moving from a purely descriptive system toward a more integrated and biologically informed model of risk assessment.
Indexed as
Identifiers
42115324What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.